GNPX – genprex, inc. (US:NASDAQ)
Stock Stats
News
12/16
09:27 am
gnpx
Low
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer [Yahoo! Finance]
12/16
09:15 am
gnpx
Medium
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
11/20
09:30 am
gnpx
High
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer [Yahoo! Finance]
11/20
09:29 am
gnpx
High
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
11/5
09:29 am
gnpx
Medium
Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
12/20
08:46 am
gnpx
Medium
Form 424B5 Genprex, Inc.
12/16
09:15 am
gnpx
High
Form 8-K Genprex, Inc. For: Dec 16
12/6
05:55 pm
gnpx
Neutral
Form 4 Genprex, Inc. For: Dec 05 Filed by: Moreno Toscano Jose Antonio
12/6
05:54 pm
gnpx
Low
Form 4 Genprex, Inc. For: Dec 05 Filed by: Wilson William R Jr.
12/6
05:52 pm
gnpx
Low
Form 4 Genprex, Inc. For: Dec 05 Filed by: LONGNECKER BRENT M
Show more
Top News Gainers
1/17 Form 424B5 Genprex, Inc. 228.6%
3/16 Form 3 Genprex, Inc. For: Mar 12 Filed by: Redman Michael Thomas 105.6%
11/19 Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers 63.2%
1/23 Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market 32.1%
2/11 Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes 26.8%
1/29 Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy 24.4%
2/20 Form 8-K Genprex, Inc. For: Feb 19 22.0%
1/31 Form SC 13G Genprex, Inc. Filed by: INTRACOASTAL CAPITAL, LLC 18.3%
4/21 Form 8-K Genprex, Inc. For: Apr 15 18.2%
2/21 Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants 14.2%
Top News Decliners
11/20 Genprex Announces $1.26 Million Registered Direct Offering -35.5%
1/23 Genprex Inc (NASDAQ: GNPX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -34.3%
2/19 Form S-3MEF Genprex, Inc. -33.3%
11/22 Form 8-K Genprex, Inc. For: Nov 20 -15.3%
3/31 Form 3/A Genprex, Inc. For: Mar 18 Filed by: Wilson William R Jr. -9.8%
3/20 Form 3 Genprex, Inc. For: Mar 18 Filed by: Wilson William R Jr. -9.2%
1/21 Form 8-K Genprex, Inc. For: Jan 21 -8.7%
12/10 Form PRE 14A Genprex, Inc. For: Jan 27 -8.4%
10/4 Form S-3/A Genprex, Inc. -8.0%
3/3 Genprex to Present at the 2020 LD Micro Virtual Conference -7.5%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3